<DOC>
	<DOCNO>NCT00557206</DOCNO>
	<brief_summary>Patient receive oxaliplatin docetaxel long progression free survival patient receive standard care .</brief_summary>
	<brief_title>Oxaliplatin Docetaxel Recurrent Metastatic Head Neck Cancer</brief_title>
	<detailed_description>Oxaliplatin : 130mg/m2 give day 1 intravenous injection ; Docetaxel : 60mg/m2 give day 1 intravenous injection Cycles repeat every 21 day disease progression , unacceptable toxicity subject 's withdrawal .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically cytologically confirm metastatic locoregionally recurrent SCCHN deem incurable local therapy Measureable disease No prior use palliative chemo SCCHN deem incurable local therapy No prior treatment oxaliplatin docetaxel 18 year age old ECOG Performance status 01 ANC 1,500/mcl great Adequate renal function Adequate liver function Recovered acute late effect prior treatment minimum 4 week last session enrollment study Patient legal representative must able read , understand , provide informed consent Patients childbearing potential partner must agree use effective form contraception study 90 day follow last dose study medication Patients active document infection fever ( 38.5 degree celsius high ) within 3 day first schedule dose study treatment Patients active CNS metastasis Hypercalcemia relate SCCHN History prior malignancy past 5 year except curatively treat basal cell carcinoma skin , cervical intraepithelial neoplasia localize prostate cancer Patients know hypersensitivity component oxaliplatin docetaxel drug formulate polysorbate 90 Patients receive concurrent investigational therapy investigational therapy le 30 day first schedule dose study therapy Peripheral neuropathy grade 2 high Any medical condition deem Investigator likely interfere patient 's ability sign inform consent , cooperate participate study , interfere interpretation result History allogeneic transplant Known HIV Hepatitis B C ( active , previously treat )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Recurrent Disease</keyword>
	<keyword>Metastatic Disease</keyword>
	<keyword>Squamous Cell Carcinoma</keyword>
	<keyword>Multicenter</keyword>
	<keyword>Phase II</keyword>
</DOC>